OCUFLOX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCUFLOX (OCUFLOX).
Inhibits bacterial DNA gyrase and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
| Metabolism | Systemic fluoroquinolones are primarily metabolized via hepatic glucuronidation and CYP450 isoenzymes; however, ophthalmic administration results in minimal systemic absorption, so hepatic metabolism is not clinically significant. |
| Excretion | Ofloxacin is primarily excreted unchanged in the urine via glomerular filtration and tubular secretion, accounting for 70-80% of an administered dose. Approximately 4-8% is excreted in feces via biliary secretion. Renal excretion is the major route. |
| Half-life | Terminal elimination half-life is approximately 5-7 hours in patients with normal renal function. This may be prolonged to 21-56 hours in severe renal impairment (CrCl <20 mL/min), necessitating dosing adjustments. |
| Protein binding | Approximately 20% bound to serum proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.5-2.5 L/kg (range 1.2-2.9 L/kg), indicating extensive tissue penetration, including into ocular tissues, respiratory tract, and urogenital system. |
| Bioavailability | Ophthalmic administration results in negligible systemic bioavailability (<5% of dose absorbed). Oral bioavailability is approximately 98%, with peak serum concentrations achieved 1-2 hours after oral dosing. |
| Onset of Action | Following ophthalmic administration, clinical effect (e.g., bacterial conjunctivitis symptom relief) typically begins within 24-48 hours, with significant improvement by 48-72 hours. |
| Duration of Action | For ophthalmic use, duration of antimicrobial effect is approximately 6-8 hours per dose, supporting QID (four times daily) dosing. Ofloxacin levels in tears remain above MIC90 for common ocular pathogens for up to 6 hours. |
1-2 drops into the affected eye(s) every 2-4 hours for the first 2 days, then 1-2 drops 4 times daily for an additional 5 days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment as systemic absorption is minimal. |
| Liver impairment | No dosage adjustment required for hepatic impairment as systemic absorption is minimal. |
| Pediatric use | 1-2 drops into the affected eye(s) every 2-4 hours for the first 2 days, then 1-2 drops 4 times daily for an additional 5 days. Safety and efficacy in children <1 year have not been established. |
| Geriatric use | No specific dosage adjustment required; use same dosing as adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OCUFLOX (OCUFLOX).
| Breastfeeding | Unknown if excreted in human milk. Caution advised. M/P ratio not available. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of teratogenicity at doses up to 810 mg/kg/day (approximately 750 times the human ophthalmic dose). Risk cannot be ruled out; use only if potential benefit justifies potential risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to ofloxacin or any component of the formulation.","Systemic fluoroquinolones are contraindicated in patients with known quinolone-induced tendonitis/tendon rupture; however, this caution is less relevant for ophthalmic use."]
| Precautions | ["Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.","Hypersensitivity reactions: rare but can be serious, including anaphylaxis, Stevens-Johnson syndrome.","Patients should not wear contact lenses during treatment of bacterial conjunctivitis.","Ophthalmic solutions may cause transient stinging or burning upon instillation."] |
Loading safety data…
| No specific monitoring required beyond usual prenatal care. Monitor for adverse effects in infant if used near term. |
| Fertility Effects | No known effects on fertility. Animal studies at high oral doses showed no impairment. |